Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Blood (2017)
  • Paul M. Barr, University of Rochester
  • Jennifer R. Brown, Harvard University
  • Peter Hillmen, Leeds Teaching Hospitals NHS Trust
  • Susan O'Brien, University of Texas MD Anderson Cancer Center
  • Jacqueline C. Barrientos, Hofstra University
  • Nishitha M. Reddy, Vanderbilt University
  • Steven Coutre, Stanford University
  • Stephen P. Mulligan, Royal North Shore Hospital
  • Ulrich Jaeger, Medical University of Vienna
  • Richard R. Furman, NewYork–Presbyterian Hospital
  • Florence Cymbalista, French Institute of Health and Medical Research
  • Marco Montillo, Catholic University of the Sacred Heart
  • Claire Dearden, The Royal Marsden NHS Foundation Trust
  • Tadeusz Robak, Medical University of Łódź
  • Carol Moreno, Autonomous University of Barcelona
  • John M. Pagel, Cancer Institute
  • Jan A. Burger, University of Texas MD Anderson Cancer Center
  • Samuel Suzuki
  • Juthamas Sukbuntherng
  • George Cole
  • Danelle F. James, University of California, San Diego
  • John C. Byrd, Ohio State University
Link
Disciplines
Publication Date
May 11, 2017
DOI
10.1182/blood-2016-12-737346
Citation Information
Paul M. Barr, Jennifer R. Brown, Peter Hillmen, Susan O'Brien, et al.. "Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL" Blood Vol. 129 Iss. 19 (2017) p. 2612 - 2615
Available at: http://works.bepress.com/john-pagel/11/